Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New model combines scans and genes to predict stomach cancer survival

NCT ID NCT07190040

Knowledge-focused Sponsor: Chang-Ming Huang, Prof. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 179 patients with advanced stomach cancer who had chemotherapy and surgery. Researchers used CT scans and genetic data from tumors to build a model that predicts how long patients might stay cancer-free. The goal was to improve survival predictions, not to test a new drug or treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this approach could help doctors more accurately predict which gastric cancer patients are likely to stay cancer-free after treatment, guiding personalized follow-up care.
What could go wrong
This is a small, single-center retrospective study, not a clinical trial testing a new treatment. The model needs validation in larger, diverse groups before it can be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

179 people

The number who actually took part.

Started

Jan 2019

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with locally advanced gastric cancer who underwent neoadjuvant therapy

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Gastric adenocarcinoma confirmed pathologically via gastroscopy; * Clinical staging of cT3/T4N0/+M0 with a history of receiving at least two cycles of neoadjuvant therapy * No prior history of other malignant tumors * Completion of radical gastrectomy Exclusion Criteria: * Gastric cancer originating from the remnant stomach * Absence of baseline computed tomography (CT) data prior to treatment or suboptimal CT image quality that could compromise the accuracy of radiomic information extraction * Absence of postoperative transcriptome data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer (GC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer (GC)

Contacts and locations

Locations

  • Fujian Medical University

    Fuzhou, Fujian, 350001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.